In this section you can add new consortium or search for partners or project proposals that are already defined or in their definition phase, of national, European or international calls, or projects of a private entity.
CEPI issues calls for proposals and requests for information inviting applicants to submit proposals for projects to develop vaccine candidates and support clinical trials involving vaccine candidates.
Aiming to measure the immune response to different vaccines in development against SARS-CoV-2 in a single centralized laboratory, avoiding variability, the Coalition for Outbreak Preparedness Innovations (CEPI) is looking for laboratories around the world that are related to SARS-CoV-2 vaccines, able to carry out comparative studies or have the capacity to quickly transfer technology test from other laboratories.
Applications by email (email@example.com) before May 10 at 3:00 p.m.
KBBE.2013.1.3.-05: Ecology of drug resistant bacteria and transfer of antimicrobial resistance throughout the food chain.
The previous group experience is in understanding the role of IncH plasmids in Salmonella biology. IncH plasmids are abundant within S. typhi strains (about 50% of them harbor these plasmids) and account for most of the multidrug resistance (MDR) phenotypes of plasmid origin in this microorganism. In the recent past, the group has studied the regulation of the temperature-dependent conjugation of these plasmids, as well as the role of a global modulator encoded by the IncH plasmid R27, the H-NS protein. Recent data, yet unpublished, evidence that these plasmids strongly modify the global transcriptome of the host strain, modifying thus fitness. We propose identifying the modulators that facilitate plasmid-chromosome cross-talk. Interfering with these modulators might thus alter plasmid-chromosome cross-talk and hence reduce fitness of these strains, making them more sensitive to the host defenses, or leading to plasmid loss which, in turn, results in loss of the MDR phenotype.
The objective of the R&D project is the development of Heparin from animal organs (intestines, lungs) of different origin from the pig (such as camels) and that would be used for the production of derivatives (Sodium enoxaparin and Tinziparin). The Spanish company would be mainly involved in the innovative development of bioactive molecules with potential commercial interest. More information: You can consult more details about the consortium you can contact the Algerian researcher Dr. Mourad Belkhelfa directly (firstname.lastname@example.org / email@example.com). More information on the ALGESIP call: you can contact Cristina Gracia firstname.lastname@example.org, José Manuel Durán email@example.com or Laura Simarro firstname.lastname@example.org.